D.S. Zolotyh
Ph.D. (Pharm.) Associate Professor, Analytical Chemistry Department,
Pyatigorsk Medical and Pharmaceutical Institute (Pyatigorsk, Russia)
Z.V. Dayronas
Dr.Sc. (Pharm.), Professor, Department of Pharmacognosy, Botany and Technology of Phytopreparations,
Pyatigorsk medical and pharmaceutical institute (Pyatigorsk, Russia)
D.I. Pozdnyakov
Ph.D. (Pharm.), Head of Living System Laboratory,
Associate Professor of Department of Pharmacology with Clinical Pharmacology Course,
Pyatigorsk Medical and Pharmaceutical Institute (Pyatigorsk, Russia)

Benzopyran-2-oh derivatives are characterized by an extensive spectrum of pharmacological activity, among which antiviral properties are particularly distinguished. It is worth noting that both natural derivatives of benzopyran-2-one and their semi-synthetic analogues have antiviral activity. It is par-ticularly relevant to evaluate the effectiveness of benzopyran-2-one derivatives in relation to the SARS-CoV-2 virus. A number of studies indicate that benzopyran-2-ones are able to suppress the main virulence factors of SARS-CoV-2: the receptor-binding domain of the S-protein, the main and papain-like proteases. As SARS-CoV-2 inhibiting agents, hebulinic acid and punicalagin are of the greatest interest, which combine a polyvalent mechanism of antiviral action, high efficiency and low toxicity.

antiviral properties
benzopyran-2-one derivatives

  1. Hyaying Fan, Zhenfang Gao, Kai Ji et al. The in vitro and in vivo anti-inflammatory effect of osthole, the major natural
  2. coumarin from Cnidium monnieri (L.) Cuss, via the blocking of the activationof the NF-κB and MAPK/p38 pathways. Phytomedicine. 2019; 58: 152864
  3. Toshihiro Aoki, Ikumi Hyohdoh, Noriyuki Furuichi et al. Optimiz-ing the Physicochemical Properties of Raf/MEK Inhibitors by Ni-trogen Scanning. ACS Med. Chem. Lett. 2014; 5(4): 304309.
  4. Lan Xie, Donglei Yu, Carl Wild et al. Anti-AIDS Agents. 52. Syn-thesis and Anti-HIV Activity of Hydroxy-methyl(3′R,4′R)-3′,4′-Di-O-(S)-camphanoyl-(+)-cis-khellac-tone Derivatives. J. Med. Chem. 2004; 47: 756760.
  5. Jian Tang, Keduo Qianb, Bei-Na Zhang, et. al. Anti-AIDS agents 82: Synthesis of seco-(3’R,4’R)-3’,4’-di-O-(S)-cam-phanoyl-(+)-cis-khellactone (DCK)derivatives as novel anti-HIV agents. Bioor-ganic & Medicinal Chemistry. 2010; 18: 4363–4373
  6. Xuemei Yu, Sainz Bruno (Jr.), Petukhov Р.A., et al. Identification of Hepatitis C Virus Inhibitors Targeting Different Aspects of Infec-tion Using a Cell-Based Assay. Antimicrobial Agents and Chemo-therapy. 2012; 56(12): 61096120.
  7. Jih Ru Hwu, Shu-Yu Lin, Shwu-Chen Tsay, et al. Coumarin-Purine Ribofuranoside Conjugates as New Agents against Hepatitis C Vi-rus. J. Med. Chem. 2011; 54: 2114–2126.
  8. Kudo E., Taura M., Matsuda K., et al. Inhibition of HIV-1 replica-tion by a tricyclic coumarin GUT-70in acutely and chronically in-fected cells. Bioorganic & Medicinal Chemistry Letters. 2013; 23: 606609.
  9. V’kovski Ph., Kratzel A., Steiner S., et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nature Reviews Mictrobiology. 2021; 19: 155170.
  10. Arya R., Kumari S., Pandey B., et al. Structural insights into SARS-CoV-2 proteins. Journal of Molecular Biology. 2021; 433: 166725.
  11. Banerjee R., Perera L., Tillekeratne L.M.V. Potential SARS-CoV-2 main protease inhibitors. Drug Discov Today. 2021; 26(3): 804816.
  12. Ullrich S., Nitsche C. The SARS-CoV-2 main protease as drug tar-get. Bioorg. Med. Chem. Lett. 2020; 1 (30(17)): 127377.
  13. Du R., Cooper L., Chen Z., et al. Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro. Antiviral Res. 2021; 190: 105075.
  14. Malla Tika R., Tumber A., John T., et al. Mass spectrometry re-veals potential of β-lactamsas SARS-CoV-2 Mpro inhibitors. Chem. Commun. 2021; 57: 1430.
  15. Loschwitz J., Jackering A., Keutmann M., et al. Novel in-hibitors of the main protease enzyme of SARS-CoV-2 iden-tified viamolecular dynamics simulation-guided in vitro assay. Bioorganic Chemistry. 2021; 11: 104862.
  16. Milligan J.C., Zeisner T.U., Papageorgiou G., et al. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp5 main protease. Biochem. J. 2021; 16; 478(13): 24992515.
  17. Hartenian E., Nandakumar D., Lari A. The molecular virology of coronaviruses. J. Biol. Chem. 2020; 11; 295(37): 1291012934.
  18. Suručić R., Travar M., Petković M., et al. Pomegranate peel extract polyphenols attenuate the SARS-CoV-2 S-gly-coprotein binding ability to ACE2 Receptor: In silico and in vitro studies. Bioorg. Chem. 2021; 114: 105145.
  19. Mouffouk C., Mouffouk S., Mouffouk S., et al. Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CLpro and PLpro), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2). Eur. J. Pharmacol. 2021; 15, 891: 173759.
  20. Chaudhuri Ratan K. Methods and composition for mitigating symptoms of acute respiratory distress syndrome. U.S. Patent № US 2021/0236580 A1. 2021.
  21. Bestle D., Heindl M.R., Limburg H. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human air-way cells. Life Sci Alliance. 2020; 23 (3(9)): e202000786
  22. Kiba Y., Oyama R., Misawa S., et al. Screening for inhibitory ef-fects of crude drugs on furin-like enzymatic activities. J. Nat. Med. 2021; 75(4): 10801085.
  23. Gribbon P., Zaliani A., Ellinger B., et al. Composition for corona-virus infection treatment and/or prevention. World Intellectual Prop-erty Organization Patent № WO 2021/198440 A1. 2021.